Advances in Cancer Treatment: New Findings from US and Italian Research

Strategic Insights -

Researchers in the United States and Italy have reported significant advances in cancer treatment, focusing on novel approaches to targeting cancer cells and angiogenesis. Study findings provide new insights into the potential of combining therapies to achieve better treatment outcomes while minimizing side effects. By investigating the role of G protein signaling in angiogenesis and the effects of gemcitabine on tumor angiogenesis, scientists have made significant strides in understanding the mechanisms of cancer growth and progression.

Key Takeaways:

  • Study 1: Cancer treatments targeting G protein may augment antiangiogenesis therapy. Researchers found that blocking VEGF function using a humanized anti-VEGF antibody may cause significant side effects, but cotargeting G protein- and VEGF-dependent pathways could lead to a safer and more efficacious therapeutic regimen.
  • Study 2: Pancreatic cancer images reveal the effects of gemcitabine on tumor angiogenesis. Gemcitabine significantly decreased the mean nascent blood vessel density in the tumor as well as decreased tumor volume, demonstrating its inhibitory effects on angiogenesis and tumor growth.
  • Study 3: Targeted tumor necrosis factor-alpha delivery to tumor vessels induces a therapeutic T cell-mediated immune response. A single systemic administration of L19mTNF alpha, in combination with melphalan, induced complete and long-lasting tumor eradication in tumor-bearing mice, triggering the generation of a specific T cell-based immune response that protected the animals from a second tumor challenge.
  • Names: T. Leung, J.D. Robishaw, Y. Amoh, M. Bouvet, E. Balza, L. Zardi
  • Programs/Initiatives: Geisinger Medical Clinic, Weis Center Research, University of California, San Diego, Center Cancer, Department of Surgery, Istituto Nazionale per la Ricerca sul Cancro
  • Constructs: Zebrafish G protein-gamma 2 is required for VEGF signaling during angiogenesis, Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine

Statistics:

  • Study 1: 83% complete tumor regression in BALB/c mice with WEHI-164 fibrosarcoma, 33% complete tumor regression in animals with C51 colon carcinoma
  • Study 2: Gemcitabine significantly decreased the mean nascent blood vessel density in the tumor by 45%, and decreased tumor volume by 23%
  • Study 3: 83% complete and long-lasting tumor eradication in tumor-bearing mice treated with L19mTNF alpha and melphalan, 73% protection against syngeneic tumor cells of different histologic origin

Sources:

  • Leung, T., et al. "Zebrafish G protein-gamma 2 is required for VEGF signaling during angiogenesis." Blood, 2006;108(1):160-166.
  • Amoh, Y., et al. "Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine." Journal of Surgical Research, 2006;132(2):164-169.
  • Balza, E., et al. "Targeted delivery of tumor necrosis factor-alpha to tumor vessels induces a therapeutic T cell-mediated immune response that protects the host against syngeneic tumors of different histologic origin." Clinical Cancer Research, 2006;12(8):2575-2582.